ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Caffeine

Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.

Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.

Drug pageCaffeine: every studyMany companies study it; this page follows only the 16 they lead. All 247 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 22, 201316 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheimits history only60 open or runningphase 3since Aug 22, 2013Jun 13, 2013none ahead
GlaxoSmithKlineits history only50 open or runningphase 4since Nov 3, 2011Mar 1, 2007none ahead
Pfizer20 open or runningphase 3since Aug 8, 2016Aug 8, 2016none ahead
Hypera Pharmaits history only10 open or runningphase 3since Jul 28, 2010Jul 28, 2010none ahead
Novartisits history only10 open or runningphase 4since Nov 23, 2010Nov 23, 2010none ahead
Sanofiits history only10 open or runningphase 3since Aug 31, 2011Aug 31, 2011none ahead

Also a collaborator on its studies: Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 8, 2016First study: phase 3 study in PainFirst studyNCT02863575 · 374 enrolled · United States
  2. Dec 3, 2020Phase 1 study in Healthy ParticipantsNCT04655040 · 12 enrolled · United States

TargetBeta

“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule

Studies

All 2 Pfizer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04655040Healthy Participants · United States1CompletedMar 5, 202112
NCT02863575Pain · United States3CompletedApr 6, 2018374

How it is read

Names in the registry

  • “Caffeine”, 11 entries
  • “caffeine”, 4 entries
  • “ibuprofen + caffeine”, 3 entries
  • “Paracetamol and Caffeine”, 2 entries
  • “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.